IMPEL NEUROPHARMA INC (IMPL): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMPL Stock Price Chart Interactive Chart >
IMPL Price/Volume Stats
|Current price||$6.95||52-week high||$34.75|
|Prev. close||$6.62||52-week low||$5.72|
|Day high||$7.03||Avg. volume||104,288|
|50-day MA||$6.78||Dividend yield||N/A|
|200-day MA||$9.49||Market Cap||161.07M|
IMPEL NEUROPHARMA INC (IMPL) Company Bio
Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Most Popular Stories View All
IMPL Latest News Stream
|Loading, please wait...|
IMPL Latest Social Stream
View Full IMPL Social Stream
Latest IMPL News From Around the Web
Below are the latest news stories about Impel Neuropharma Inc that investors may wish to consider to help them evaluate IMPL as an investment opportunity.
Investment company Epiq Partners, Llc (Current Portfolio) buys Macquarie Infrastructure Holdings LLC, AquaBounty Technologies Inc, Pfizer Inc, WisdomTree U.S.
Trudhesa ™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company''s Guidance Range Achieved Broad and Favorable Trudhesa ™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022 SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL ), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today provided updates on Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) launch progress ...
With an October 2021 launch, Impel NeuroPharma saw 4.2K prescriptions written for its Trudhesa (dihydroergotamine mesylate) nasal spray for acute migraine headaches in Q4.
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable Trudhesa™ Payer Coverage with Signed Agreements Covering 80% of U.S. Commercial Lives Planned Initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in Q1 2022; Results anticipated Q4 2022 SEATTLE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage
Newtown, PA, based Investment company Towercrest Capital Management (Current Portfolio) buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, Invesco S&P 500 Equal Weight ETF, Impel NeuroPharma Inc, Kala Pharmaceuticals Inc, sells Vanguard FTSE Emerging Markets ETF, International Business Machines Corp during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Towercrest Capital Management.
IMPL Price Returns